A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Trial Profile

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2018

At a glance

  • Drugs Cediranib (Primary) ; Olaparib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2018 Planned primary completion date changed from 31 May 2018 to 30 Jun 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 30 Jun 2016 Planned number of patients changed from 121 to 126.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top